By Colin Kellaher Shares of Ascendis Pharma AS rose sharply in premarket trading Monday after the biopharmaceutical company said the U.S. Food & Drug Administration turned away its. | May 1, 2023
The FDA has rejected Pfizer’s somatrogon, a long-acting form of human growth hormone designed for once-weekly dosing. The setback delays Pfizer and partner Opko Health from competing against a newly approved human growth hormone drug from Ascendis Health that is also designed for once-weekly dosing.